LYMPHIR™ (E7777)

About Citius Pharmaceuticals

Citius Pharmaceuticals is a late-stage biopharma company with a mission to develop and commercialize first-in-class critical care products. Its key achievement is the FDA approval and commercialization of LYMPHIR™ for cutaneous T-cell lymphoma, marking its transition to a commercial-stage entity. The company's strategy is built on a diversified pipeline targeting high-need areas like catheter-related infections and adjunct cancer care, with a core focus on accelerating promising therapies through late-stage development. Financially, it operates as a micro-cap public company, navigating the capital-intensive path of drug development while managing a lean operational structure.

Therapeutic Areas

Other Cutaneous T-cell lymphoma (CTCL) Drugs